ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RPID Rapid Micro Biosystems Inc

0.77
-0.01025 (-1.31%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Rapid Micro Biosystems Inc NASDAQ:RPID NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.01025 -1.31% 0.77 0.68 0.794 0.795 0.762 0.78 7,779 22:32:27

Rapid Micro Biosystems to Participate in the Morgan Stanley 21st Annual Global HealthCare Conference

06/09/2023 9:15pm

GlobeNewswire Inc.


Rapid Micro Biosystems (NASDAQ:RPID)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Rapid Micro Biosystems Charts.

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference.

Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a 30-minute question-and-answer session with the host analyst on Tuesday, September 12, 2023 at 7:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay for at least 180 days after the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.

Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
mbeaulieu@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

1 Year Rapid Micro Biosystems Chart

1 Year Rapid Micro Biosystems Chart

1 Month Rapid Micro Biosystems Chart

1 Month Rapid Micro Biosystems Chart

Your Recent History

Delayed Upgrade Clock